Print friendly version
Mucopolysaccharidosis type II
Other Names for this Disease
- Attenuated MPS (subtype; formerly known as mild MPS II)
- Hunter syndrome
- I2S deficiency
- Iduronate 2-sulfatase deficiency
- MPS 2
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.
- GeneReviews provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions. Click on the link to view the article on this topic.
Clinical Trials & Research for this Disease
- ClinicalTrials.gov lists trials that are studying or have studied Mucopolysaccharidosis type II. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.
Medical ProductsThe medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.
The FDA has approved this product to be used in this manner.
|Indicated for patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Idursulfase has been shown to improve walking capacity in these patients|
|More Information about this product||Drug Information Portal|